Pfizer Appoints Former Novartis Executive Jeffrey Legos as Chief Oncology Officer to Strengthen Cancer Drug Portfolio
核心洞察
Pfizer has named Jeffrey Legos, a veteran Novartis executive with over two decades of oncology drug development experience, as its new chief oncology officer, replacing interim leader Roger Dansey.
Under Legos' leadership at Novartis, the company secured notable approvals for drugs like Pluvicto and Kisqali, contributing to over 40 regulatory approvals throughout his career.
The appointment comes as Pfizer aims to revitalize its oncology division, which generated about 25% of its $64 billion revenue in 2023, amid declining COVID-19 product sales and upcoming patent expirations.
Pfizer announced Wednesday the appointment of Jeffrey Legos as its new chief oncology officer, marking a strategic move to strengthen its cancer drug portfolio amid various business challenges. Legos, who previously led Novartis' hematology and oncology drug development since 2015, will report directly to Chris Boshoff, Pfizer's head of R&D.
The leadership change comes at a crucial time for Pfizer's oncology division, which represents approximately a quarter of the company's $64 billion annual revenue. Legos succeeds interim chief oncology officer Roger Dansey, who joined Pfizer following the Seagen acquisition and will retire after the transition.
Strategic Significance and Market Context
Pfizer faces multiple challenges, including declining revenues from COVID-19 products Comirnaty and Paxlovid, and impending patent expirations for key drugs like Xtandi and Eliquis. The company's stock has experienced a significant decline, losing about half its value since its 2021 peak of nearly $60 per share.
Legos brings impressive credentials to his new role, having contributed to over 40 regulatory approvals of drugs and companion diagnostics throughout his career at both GSK and Novartis. His track record includes successful launches of significant oncology products, notably the radiopharmaceutical Pluvicto and the breast cancer (搜索) treatment Kisqali at Novartis.
Oncology Portfolio and Growth Strategy
Pfizer's current oncology portfolio includes several blockbuster drugs, with Ibrance leading the revenue generation. CEO Albert Bourla has outlined an ambitious growth strategy, projecting eight potential new blockbuster drugs by 2030.
Key developments in the pipeline include:
- Multiple late-stage breast cancer drugs, including a protein-degrading therapy co-developed with Arvinas
- Advanced antibody-drug conjugates (ADCs) for lung cancer, including technology acquired from Seagen
- Expanding indications for Elrexfio, a multiple myeloma drug showing early promise
- Growth opportunities for Padcev in bladder cancer, with potential to triple its eligible patient population
Market Competition and Future Outlook
The appointment comes as Pfizer navigates a competitive oncology landscape. Elrexfio faces competition from Johnson & Johnson's similar therapy and potential new entries from Regeneron. However, Bourla remains optimistic about the drug's potential to become a "mega blockbuster."
The $43 billion Seagen acquisition in 2023 has added significant capabilities to Pfizer's oncology arsenal, particularly in ADC technology. This strategic investment, combined with Legos' experienced leadership, positions Pfizer to potentially overcome its current challenges and strengthen its position in the oncology market.
The success of this leadership transition will be crucial for Pfizer as it works to restore investor confidence and drive growth through its oncology portfolio, particularly as the company moves beyond its COVID-19 revenue peak and faces increasing market pressures.